HABP2 Antibody

說明書

中文名稱：

HABP2兔多克隆抗體
貨號：

CSB-PA000069
規格：

￥1090
圖片：
Western Blot analysis of HeLa cells using HABP2 Polyclonal Antibody
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

Q14520
基因名：

HABP2
別名：

Factor seven activating protease antibody; Factor seven-activating protease antibody; Factor VII activating protein antibody; Factor VII-activating protease antibody; FSAP antibody; HABP 2 antibody; HABP antibody; Habp2 antibody; HABP2_HUMAN antibody; Hepatocyte growth factor activator like protein antibody; Hepatocyte growth factor activator-like protein antibody; HGFAL antibody; Hyaluronan binding protein 2 antibody; Hyaluronan-binding protein 2 27 kDa light chain alternate form antibody; Hyaluronic acid binding protein 2 antibody; PHBP antibody; Plasma hyaluronan binding protein antibody; Plasma hyaluronan-binding protein antibody
宿主：

Rabbit
反應種屬：

Human,Mouse,Rat
免疫原：

Synthesized peptide derived from the Internal region of Human HABP2.
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
產品提供形式：

Liquid
應用范圍：

WB, ELISA

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:2000
ELISA	1:5000

Protocols：

Western Blotting (WB) Protocol
ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Cleaves the alpha-chain at multiple sites and the beta-chain between 'Lys-53' and 'Lys-54' but not the gamma-chain of fibrinogen and therefore does not initiate the formation of the fibrin clot and does not cause the fibrinolysis directly. It does not cleave (activate) prothrombin and plasminogen but converts the inactive single chain urinary plasminogen activator (pro-urokinase) to the active two chain form. Activates coagulation factor VII. May function as a tumor suppressor negatively regulating cell proliferation and cell migration.
基因功能參考文獻：
1. The presence of the noninheritable V600E BRAF mutation in this family supports Knudson's "double-hit" hypothesis for cancer development and suggests the involvement of more than 1 gene in the clinical expression of familial nonmedullary thyroid carcinoma. PMID: 29895015
2. The MI-SNP and MII-SNP FSAP gene polymorphisms were not predictive or prognostic biomarkers for coronary artery diseaseor its main risk factors. PMID: 29927903
3. NETs bind to FSAP, but do not activate pro-FSAP unless histones are released from NETs by DNAse. This activation of FSAP is likely to be important in diminishing the cytotoxic effect of histones, thus limiting the damaging effect of NETosis. PMID: 29178989
4. Regulation of gene expression by FSAP in vascular smooth muscle/endothelial cells accounts for its vasculo-regulatory properties. PMID: 28881271
5. The extent of CAC in women is positively associated with total FSAP, but negatively associated with the specific activity of FSAP suggesting that FSAP may play a role in the evolution of CVD in women. PMID: 28548975
6. Report peptide substrates used in determining substrate specificity of Factor VII activating protease. PMID: 28726978
7. Two of 20 probands from families with history of PTC and breast carcinoma (BC) were evaluated by whole exome sequencing (WES) revealing HABP2 p.G534E. PMID: 28402931
8. No significant association was found between rs11196288 and early-onset ischemic stroke, large artery atherosclerotic stroke, or small vessel disease stroke. rs11196288 presented significant effect on late-onset SVD stroke susceptibility in the older population. PMID: 28501930
9. study on a wide series of familial non-medullary thyroid cancers indicates that the HABP2(G534E) variant is frequent, but does not segregate with the disease PMID: 28222214
10. Letter: G534E variant in HABP2 is not associated with non-medullary thyroid cancer in the Spanish population. PMID: 27245704
11. mutations were not found in familial non-medullary thyroid cancer, and the G534E variant is not the underlying genetic defect in a large sample of sporadic non-medullary thyroid cancer from the Middle East. PMID: 26906432
12. Study showed that lower FSAP antigen plasma levels were associated with a higher chance of arterial recanalization after tissue plasminogen activator treatment, suggesting an involvement of FSAP in tissue plasminogen activator-induced clot lysis. FSAP antigen determination might be useful in predicting tissue plasminogen activator response in stroke patients. PMID: 27073188
13. HABP2 polymorphisms are not associated with thyroid cancer. PMID: 27873212
14. the promoter activity, which could phenocopy changes in Habp2 mRNA in response to TGF-beta, was found to be located in the 177-bp region upstream of the transcription start site, and this region did not contain any SMAD binding sites. PMID: 27462075
15. Results show that G534E germline variant in HABP2 does not account for the familial nature of nonmedullary thyroid cancer in Australian kindreds but and is common in the general population. PMID: 27530615
16. omology modeling suggested that the Glu-221 side chain could sterically hinder insertion of the N terminus into the HABP2 protease domain, helping to explain the detrimental effects of Glu-221 substitution on HABP2 activity. PMID: 28246168
17. The data do not support the pathogenicity of the HABP2 c.1601G > A variant but highlight the existence of a new one that should be more extensively searched for in familial papillary thyroid carcinoma patients and its pathogenicity more carefully evaluated. PMID: 28089742
18. No evidence supporting a role for the HABP2 G534E variant (SNP rs7080536) in papillary thyroid carcinoma. PMID: 26745718
19. HABP2 G534E appears to be a susceptibility gene in a subgroup of Familial Non-Medullary Thyroid Cancer (FNMTC), providing important diagnostic implications for this hereditary thyroid cancer. PMID: 26832773
20. HABP2, which encodes an extracellular serine protease involved in coagulation, fibrinolysis, and inflammatory pathways, may be a genetic susceptibility locus for early-onset stroke. [Meta-Analysis] PMID: 26732560
21. Patients with Gram-negative sepsis caused by B. pseudomallei have abundant FSAP activation, which significantly correlates with stage of disease. PMID: 25370187
22. results suggest that the HABP2 G534E variant is a susceptibility gene for familial nonmedullary thyroid cancer PMID: 26222560
23. CD44 expression in squamous cell carcinoma of the penis cannot predict the need of performing inguinal lymphadenectomy. PMID: 25847894
24. FSAP functions in initiation and progression of hepatic fibrosis PMID: 24497464
25. The possible effects of omega-3 FA on clinical AF potential could be linked with modulation of circulating FSAP levels. PMID: 23575879
26. FSAP activates the NF-kappaB pathway and the associated downstream pro-inflammatory factors in monocytic cells PMID: 24075769
27. The study demonstrated that a single nucleotide polymorphism (Marburg I) in the FSAP gene (HABP-2)results in a weak proteolytic activity against all substrates including FVII. PMID: 22906531
28. Lower FSAP expression is associated with enhanced liver fibrosis and inflammation in patients with chronic hepatic disorders and murine experimental liver injury. PMID: 22989567
29. Data indicate that FSAP mediates proteolytic cleavage and activation of bone morphogenetic protein-2 (BMP-2). PMID: 23341458
30. High levels of FSAP activity were predictive of adverse events during follow-up, suggesting its potential role in risk stratification and clinical management of CAD patients. PMID: 22850287
31. We conclude that FSAP Marburg-I genotyping may be used to determine the risk for thromboembolic disorders in patients with suspected thrombophilia and known DVT or PE. PMID: 22421107
32. Report tissue factor pathway inhibitor as an efficient inhibitor of factor VII-activating protease. PMID: 22449009
33. Increased plasma FSAP antigen levels and activity were associated with ischemic stroke and all main etiologic subtypes. PMID: 22409238
34. These results indicate that polymorphisms in the regulatory region of HABP2 gene could influence gene expression levels in the receptive endometrium and be one reason for infertility complications in women with unexplained infertility. PMID: 21098215
35. Data suggest that plasma FSAP activity levels were higher in women with recurrent pregnancy loss than in fertile women. PMID: 22383781
36. A high correlation between FSAP activity and C5a was found in multiple trauma patients PMID: 22308306
37. Factor VII-activating protease promotes the proteolysis and inhibition of tissue factor pathway inhibitor. PMID: 22116096
38. SNP analyses indicate an important role for FSAP in the regulation of the haemostasis system as well as fibroproliferative inflammatory processes. [review] PMID: 21655671
39. these results suggest pathophysiological relevance of histone-dependent pro-PHBP activation in hyperinflammatory process. PMID: 21600885
40. Marburg I polymorphism of FSAP might not be associated with cerebral infarction. PMID: 20045910
41. identified laccaic acid as a potent inhibitor of the protease in terms of both autoactivation of the PHBP proenzyme (IC(50) = 0.35-0.55 microg/ml) and the catalytic activity of the active enzyme (IC(50) = 1.1 microg/ml). PMID: 21071862
42. FSAP inhibited platelet-derived growth factor-stimulated proliferation, migration, p42/p44 MAPK phosphorylation and collagen III synthesis of the human pulmonary fibroblasts. PMID: 20818495
43. The protein products HABP2 and HYAL1 were associated with plasma PAI-1 concentration and play key roles in hyaluronan metabolism, providing genetic evidence to link these pathways. PMID: 20558613
44. Report that polyamine induces the formation of pro-PHBP autoactivation complex, in which an intermolecular interaction between N-terminal region and the third EGF-like domain (E3) plays a role. PMID: 19817990
45. Hyaluronic acid binding protein 2 (HABP2) negatively regulates vascular integrity via activation of protease-activated receptor/RhoA/Rho kinase signaling. It represents a potential therapeutic target for syndromes of increased vascular permeability. PMID: 20042707
46. The frequency of factor VII-activating protease Marburg I is significantly increased in patients with a history of venous thromboembolism (VTE) or idiopathic VTE compared to healthy controls. PMID: 15486068
47. An interactive effect upon risk was found between the 511E allele and elevated levels of cholesterol and triglyceride or fibrinogen. The findings support the proposal that the FSAP 511E allele exacerbates atherosclerosis or its clinical sequelae PMID: 15543324
48. extracellular RNA, present at sites of cell damage or vascular injury, can serve an important as yet unrecognized cofactor function in haemostasis by inducing (auto-)activation of FSAP through a novel surface-dependent mechanism PMID: 15654766
49. Marburg I polymorphism of factor VII-activating protease does not have a role in venous thrombosis [letter] PMID: 15933067
50. exhibits a significant growth factor-like activity on quiescent human lung and dermal fibroblasts PMID: 16153533
顯示更多

收起更多
相關疾?。?/div>
Thyroid cancer, non-medullary, 5 (NMTC5)
亞細胞定位：

Secreted. Note=Secreted as an inactive single-chain precursor and is then activated to a heterodimeric form.
蛋白家族：

Peptidase S1 family
組織特異性：

Ubiquitously expressed.
數據庫鏈接：

HGNC: 4798

OMIM: 603924

KEGG: hsa:3026

STRING: 9606.ENSP00000277903

UniGene: Hs.422542

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human